Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$892.87 ▼ -4.98
(-0.56%)
MKT CAP: $55.72B • VOL: 462.6K
52W L $662 52W H $1,073
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$750
MEDIAN
$1,000
MEAN
$1,018
HIGH
$1,214
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ARGX TAPE
ARGX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $1,080.37 | $1,026.80 | 2025-02-14 | $812.51 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1,125.02 | $1,053.59 | 2025-02-06 | $839.30 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1,017.87 | $982.16 | 2025-01-29 | $857.16 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $910.73 | — | 2025-01-17 | $875.01 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $785.73 | $848.23 | 2025-01-09 | $794.65 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $1,062.52 | $928.58 | 2024-12-18 | $776.80 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $866.08 | $901.80 | 2024-12-04 | $830.37 | -4.3% | 48% | C |